ProCE Banner Activity

CE / CME

Optimizing Identification and Management of Postpartum Depression: An Update for NPs and PAs (Part 1)

Video

Part 1 of this 2-part Medical Minute series provides best practices for screening and diagnosis of PPD with perspectives from a nurse midwife and a psychiatrist specializing in women’s health.

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: February 13, 2024

Expiration: February 12, 2025

Share

Faculty

Anita H. Clayton

Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Erin Johnson Cole

Erin Johnson Cole, DNP, CNM, WHNP, NCMP-BC, NCMP, CLC, FACNM

Associate Professor (Clinical), College of Nursing
Adjunct Assistant Professor, OB/Gyn Department, School of Medicine
University of Utah
Salt Lake City, Utah

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with National Association of Nurse Practitioners in Women's Health

ProCE Banner

Supporters

Supported by an education grant from Sage Therapeutics, Inc. and Biogen.

Biogen

Sage Therapeutics, Inc.

Partners

NPWH

ProCE Banner

Target Audience

The educational program is intended for primary care and specialty NPs and PAs, including those who practice in family medicine and obstetrics/gynecology, as well as nurse midwives who manage patients with PPD. The identified target audience will benefit from this education by gaining the knowledge and strategies necessary to routinely integrate PPD screening and management into clinical practice.

Program Learning Goal

The goal of this educational program is to improve NP and PA knowledge, competence, and performance related to identification of risk factors for and clinical presentation associated with PPD, achieving an early diagnosis to initiate prompt treatment, and understanding new and emerging therapies to individualize treatment and optimize patient outcomes.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess the impact of the burdensome effects of PPD on patients and families and the consequences if left untreated

  • Incorporate screening methods into clinical practice that allow for early diagnosis of  and treatment initiation for PPD

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

‌All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Anita H. Clayton, MD, DLFAPA, IF

Wilford W. Spradlin Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
University of Virginia School of Medicine
Charlottesville, Virginia

Anita H. Clayton, MD, DLFAPA, IF: grants: Daré Bioscience, Janssen, Neumora Therapeutics, Otsuka, Relmada Therapeutics; consultant/advisor: AbbVie, Biogen, Brii Biosciences, Fabre-Kramer, Initiator Pharma, Janssen Research & Development, Mycomedica Life Sciences, PureTech Health, Reunion Neuroscience, S1 Biopharma, Sage Therapeutics, Sertsei Pharmaceuticals, Vella Bioscience; stock/stock options: Euthymics, S1 Biopharma.

Erin Johnson Cole, DNP, CNM, WHNP, NCMP-BC, NCMP, CLC, FACNM

Associate Professor (Clinical), College of Nursing
Adjunct Assistant Professor, OB/Gyn Department, School of Medicine
University of Utah
Salt Lake City, Utah

Erin Johnson Cole, DNP, CNM, WHNP, NCMP-BC, NCMP, CLC, FACNM, has no relevant financial relationships to disclose.

Michael Asbach, DMSc, PA-C, Psych-CAQ
Associate Director International Psychiatry
DENT Neurologic Institute
Buffalo, New York

Michael Asbach, DMSc, PA-C: consultant/advisor/speaker: AbbVie, Avanir, Intracellular, Janssen, Neurocrine, Otsuka, Sage/Biogen.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from February 13, 2024, through February 12, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a post-test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

 

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until February 12, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.